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Abstract
Background: Fatigue is a disabling symptom associated with reduced quality of life in various populations living
with chronic illnesses. The transfer of knowledge about fatigue from one group to another is crucial in both
research and healthcare. Outcomes should be validly and reliably comparable between groups and should not be
unduly influenced by diagnostic variations. The present study evaluates whether the Fatigue Severity Scale 7-item
version (FSS-7) demonstrates similar item hierarchy across people with multiple sclerosis, stroke or HIV/AIDS to
ensure valid comparisons between groups, and provide further evidence of internal scale validity.
Methods: A secondary comparative analysis was performed using data from three different studies of three
different chronic illnesses: multiple sclerosis, stroke and HIV/AIDS. Each of these studies had previously concluded
that the FSS-7 has better psychometric properties than the original FSS for measuring fatigue interference. Data
from 224 people with multiple sclerosis, 104 people with stroke and 316 people with HIV/AIDS were examined. Item
response theory and a Rasch model were chosen to analyze the similarity of the FSS-7 item hierarchy across the
three diagnostic groups.
Results: Cross-sample differences were found for items #3, #5, #6 and #9 for two of the three samples, which raise
questions about item validity across groups. However, disease-specific and disease-generic Rasch measures were
similar across samples, indicating that individual fatigue interference measures in these three chronic illnesses might
still be reliably comparable using the FSS-7.
Conclusions: Some items performed differently between the three samples but did not bias person measures,
thereby indicating that fatigue interference in these illnesses might still be reliably compared using FSS-7 scores.
However, caution is warranted when comparing fatigue raw sum scores directly across diagnostic groups using the
FSS-7. Further studies of the scale are needed in other types of chronic illnesses.
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Background
Fatigue is a common and disabling symptom in many
chronic diseases. It often co-varies with depressive sym-
ptoms [1-4] and sleep impairment [5,6] and is associ-
ated with poorer self-reported health status [7,8] and
reduced quality of life [9-12]. Because fatigue is a per-
ceived phenomenon, researchers and clinicians rely on
subjective measures to indicate need for intervention or
effectiveness of treatment. When 18 fatigue measures used
in chronic illness research were reviewed, the Fatigue
Severity Scale (FSS) [13] was rated highest on robust psy-
chometric properties [14]. An advantage of the FSS is that
it is a short 9-item measure with items formulated as
statements about the fatigue experience itself (item #3),
what causes fatigue (item #2), and how fatigue interferes
with daily life (7 items).
In our prior work [15-17] we used Rasch analysis to
evaluate the psychometric properties of the original 9-
item version of the FSS within several chronic illness
groups, including multiple sclerosis (MS), stroke and
HIV/AIDS. These three illnesses were selected because
fatigue is a well-documented and prevalent symptom in
each of these patients groups [18-25]. The prior studies
[15-17] each concluded that a 7-item version of the FSS
(FSS-7) has better psychometric properties and is a reli-
able and valid measure of fatigue interference rather than
severity as indicated by the title of the measure. These
studies, as well as a study by Mills et al. [26], provided
consistent evidence regarding the relationship between the
included items and the underlying latent trait in diagnosis-
specific samples. However, we do not know whether the
FSS items function similarly across the samples and are
thus appropriate for use in comparative studies.
Rasch analysis is a useful tool for evaluating these
types of psychometric properties. It is part of the group
of modern psychometric approaches in item response
theory used to evaluate the relative endorsement, or
hierarchy of items within a measure. Rasch models sup-
port the process of validation analysis by providing a
transformation of an ordinal score into a linear, interval-
level variable. The Rasch model shows what item re-
sponses would be expected if interval scale measurement
is to be achieved. Actual response patterns, identified
in a questionnaire with a set of items intended to be
summed together, are tested against what would be
expected by the model. The hierarchical ordering of items
within the scale can also be affirmed [27]. That is, the
items can be arranged in order of relative difficulty based
on their likelihood of being endorsed given an underlying
level of the measured construct.
Although the original FSS has been used to measure
fatigue in a variety of different populations, we found no
studies that explored the stability of the item hierarchy
across different disease populations. In this context,
“stability” does not mean reliability as defined in classical
test theory, but rather reflects the similarity, consistency or
invariability of the item hierarchies across groups. If item
hierarchies vary across groups (some items are easier or
harder to agree with for one group compared to another
group), the resulting scores will be biased. Rasch analysis
addresses and evaluates the impact of such issues using dif-
ferential item functioning (DIF) [27]. Studies encompassing
several disease groups are critical for integrating evidence
to transfer knowledge about potential interventions from
one clinical specialty to another. Measures such as the FSS
must therefore be evaluated across diagnostic groups to
ensure that the scale functions comparably across groups
and is not overly influenced by diagnostic variations.
Thus, the purpose of this study was to evaluate whether
the FSS-7 demonstrates a similar item hierarchy across
three chronic illness groups (MS, stroke and HIV/AIDS)
to ensure valid comparisons between groups and pro-
vide further evidence of internal scale validity. We con-
ducted a secondary analysis of FSS data from three
different studies of samples with potential diagnostic
differences in item hierarchy. Each of these studies had
previously concluded that the FSS-7 has better psycho-
metric properties for measuring fatigue interference
than the original FSS-9 [15-17], and this study aims to
determine whether the FSS-7 can be validly and reliably
compared across illness groups.
Methods
Samples and procedures
MS
Data were collected in a longitudinal study of functioning
and disability in people with MS at an outpatient MS spe-
cialist clinic in Stockholm, Sweden. All people over
18 years of age with definite MS according to the Poser
criteria [28] who were scheduled for an outpatient ap-
pointment with their neurologist were eligible. Data were
collected at baseline and at 6-month intervals for 2 years
from 2002 to 2004. Results have been reported elsewhere
[2,19]. A total of 227 people with MS were enrolled in the
study, at baseline they had been diagnosed with MS for a
mean of 14 years (standard deviation [SD] 10 years). Data
on age and sex were collected from medical records. The
Swedish version of the original FSS was completed via
face-to-face interviews by 224 respondents at baseline;
these data were used in the current analysis.
Stroke
Data were collected at 6-month intervals for 2 years
from 2007 to 2009 as part of a Norwegian longitudinal
study of people who presented with a first-ever clinical
stroke according to the ICD–10 [29], were age 18 years
or older and had sufficient cognitive function to partici-
pate. A detailed description of the study has been
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previously reported [22]. Data on age and sex were col-
lected from medical records. The Norwegian version of the
original FSS was completed via face-to-face interviews or
mailed questionnaires. The 12-month data (n = 104) were
used for this analysis to better approximate the chronic
phase of the illness assessed in the other two samples.
HIV/AIDS.
Data were collected from 2005 to 2007 as part of a lon-
gitudinal study of people with HIV/AIDS in San Fran-
cisco, USA [24]. The study was designed to characterize
the symptom experience of people with HIV/AIDS and
to identify biological and genetic markers of the symp-
tom experience. Eligible participants were English-
speaking, 18 years or older, and diagnosed with HIV/
AIDS at least 30 days before enrollment. Individuals were
excluded if they currently used illicit drugs, worked nights,
had been pregnant in the previous 3 months, or reported
having a diagnosed sleep disorder, schizophrenia, bipolar
disorder, or dementia. Participants completed a baseline
assessment, and those not reporting significant sleep
disturbance or fatigue continued with assessments at 6-
month intervals for up to 2 years. At baseline they had
been diagnosed with HIV for a mean of 12 years (SD
7 years). The results have been reported elsewhere [24].
Self-report questionnaires were used to collect data on
age, gender, race/ethnicity, level of education, clinical char-
acteristics, and concurrent symptoms. At baseline the ori-
ginal FSS version was completed by 316 respondents, and
these data were used in the current analysis.
Data collection
Fatigue was measured with the original FSS developed
by Krupp [13]. Each item is scored on a 7–point Likert
scale ranging from 1 (“strongly disagree”) to 7 (“strongly
agree”). The mean score of the 9 items has commonly
been used to estimate fatigue interference. Findings from
recent studies in people with MS [15,26], stroke [16],
and HIV/AIDS [17] show that items #1 (“My motivation
is lower when I am fatigued”) and #2 (“Exercise brings
on my fatigue”) do not show acceptable goodness-of-fit
to the Rasch model and thus should not be included in
the mean score of the FSS. As these findings seem to be
congruent, we chose in this study to use the remaining
seven items (FSS-7) for the analysis of item hierarchy
similarity. These items assess demonstrated characteris-
tics of fatigue and focus on the extent to which fatigue
interferes with various aspects of daily functioning [17].
Ethical considerations
The MS study was approved by the ethics committee of
Karolinska Institutet in Stockholm, Sweden (reference No
449/01). The stroke study was approved by the Regional
Medical Research Ethics Committee of Health East of
Norway and the Norwegian Data Inspectorate, Norway
(reference No 2009/1468 S-07027b). The HIV study was
approved by the Committee of Human Research at the
University of California, San Francisco, USA (reference
No 10–01357).
Data analysis
Descriptive statistics were used to summarize sample
socio-demographic characteristics and FSS-7 scores.
Statistically significant differences in characteristics were
analyzed using chi-square test for categorical data and
independent sample t-test for continuous data. The level of
significance was set to p < 0.05 and all tests were two-tailed.
Item response theory and a Rasch model were chosen
to analyze the similarity of the FSS-7 item hierarchy
across the three diagnostic groups. The Rasch model
takes each item scored and adjusts the final person
measure based on relative differences in item severity.
Rasch models are also suitable for handling data where
items may be missing, so no participant was excluded
due to specific missing values [30-32].
The WINSTEPS analysis software program, version
3.69.1.16 [33] was used to conduct the Rasch analyses
in this study. Such an analysis first converts raw item
scores from a questionnaire into equal-interval measures
using a logarithmic transformation of the odds of the
actual responses. These converted values can then also
be used to examine whether the scale items measure a
one-dimensional construct [30,34]. Based upon the ac-
tual pattern of responses, the Rasch transformation sim-
ultaneously results in an estimation of a person’s fatigue
interference measure as well as measures (calibrations)
of each item along a calibrated continuum: from items
that are easier to agree with to items that are harder to
agree with. Rasch models are probabilistic and based on
theoretical assertions against which the actual pattern of
responses is validated. Although the FSS-7 uses a generic
rating scale from 1 to 7, it may not function in a similar
manner across all items, as items may demonstrate dif-
ferent response patterns even though the same generic
rating scale is used. Therefore, a partial credit model, de-
veloped for scales where ratings may differ across items,
was applied to the FSS-7 in this study.
Initially, all diagnostic subgroups were analyzed together,
resulting in disease-generic individual fatigue interfer-
ence measures for each participant. Analyses of variance
(ANOVAs) were then conducted to compare the fatigue
interference measures between the three diagnostic
groups. If a significant main effect was found, additional
Tukey post hoc tests with a significance level set at p <
0.05 were then used to identify significant pairwise dif-
ferences between the diagnostic groups.
Secondly, three separate Rasch analyses were gener-
ated in order to explore the diagnosis-specific FSS-7
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item hierarchies. A number of DIF analyses were then
performed to evaluate the similarity of relative FSS-7
item calibrations across the three diagnostic groups,
thereby determining whether bias existed for the items
among the groups. The magnitude of DIF was evaluated
using the Mantel-Haenszel statistic for polytomous
scales using log-odds estimators [35,36] in the WIN-
STEPS program. Although a Bonferroni correction yield-
ing a 1% alpha is commonly used [27], we also report
results with p < 0.05 to more conservatively evaluate the
likelihood of item bias. For the FSS-7 item hierarchies to
be considered similar across diagnostic groups and sup-
port further evidence of cross-diagnostic scale validity,
we expected that no item should have a significant DIF
between pairs of diagnostic groups.
Finally, we used the disease-specific FSS-7 item hier-
archies and generated disease-specific measures for each
participant as well. We then compared the individual
measures generated from each disease-specific FSS-7
scale with the original individual measures from the
disease-generic FSS-7 scale. This analysis aimed to ex-
plore the impact of different item hierarchies (different
tests) on the individual measures using Differential Test
Functioning (DTF). We used standardized z-compari-
sons to evaluate whether the measures generated from
the disease-specific and disease-generic FSS-7 scales dif-
fered significantly from each other, considering the level
of precision (standard error) of each individual fatigue
interference measure.
Results
In the present study, data from 224 people with MS, 104
people with stroke, and 316 people with HIV/AIDS were
analyzed. Socio-demographic characteristics and FSS-7
mean scores for the three samples, as well as significant
differences between the samples, are shown in Table 1.
Differences in fatigue between diagnostic groups
The results of the one-way ANOVA for the FSS-7 inter-
ference measures revealed a significant main effect for
diagnostic group (F [19.81] p < 0.001). Tukey post hoc
tests indicated that the MS group had significantly
higher FSS-7 scores than both the stroke group (p <
0.001) and the HIV group (p < 0.001), but the stroke
group and HIV group did not differ significantly from
each other (p = 0.79). Fatigue interference (FSS-7) scores
were converted into equal-interval measures that can
range from 0 to 100, and the means, standard deviations
and ranges for the three groups were: 1) MS: 56.1 ± 16.1
(range 6.4 – 91.9); 2) stroke: 48.6 ± 14.6 (range 6.4 –
91.9), and 3) HIV: 47.3 ± 17.3 (range 6.4 – 91.9).
Stability of relative FSS item calibrations
The relative FSS-7 item calibration hierarchies are pre-
sented in Table 2 for people with MS, in Table 3 for
people with stroke, and in Table 4 for people with HIV/
AIDS. Relative FSS-7 item difficulty calibrations for all
three samples are also illustrated in Figure 1.
In Table 5, significant DIF comparisons by diagnostic
groups are presented for each of the seven items. Dif-
ferences for item #3 (“I am easily fatigued”) were found
between MS and HIV/AIDS groups (p < 0.01) as well as
between stroke and HIV/AIDS groups (p < 0.01). Further-
more, differences were found for item #5 (“Fatigue causes
frequent problems for me”) between MS and stroke
groups (p < 0.01) and for item #6 (“My fatigue prevents
sustained physical functioning”) between MS and HIV/
AIDS groups (p < 0.05). There were also differences
Table 1 Sample socio-demographic characteristics and fatigue severity scale-7 mean scores
Socio-demographic
variables
MS N = 224
(Group A)
Stroke N = 104
(Group B)
HIV/AIDS N = 316
(Group C)
Significant differences between
groups (p < 0.05)
Age: years (M ± SD)* 46.5 ± 12.4 68.0 ± 12.8 45.1 ± 8.4 A,C < B
Range 20 – 75 29 – 91 22 – 77
Years since diagnosis (M ± SD)* 14 (10) 1 (0.1) 12 (7) A,C > B
Range 0 – 44 1 – 1 0 – 27
Gender: n (%)
Women 149 (68) 41 (39) 77 (24) A > B > C
Men (75 (32) 63 (61) 216 (69)
Transgender 23 (7)†
Living with partner: n (%) 152 (69) 70 (67) 109 (35) A,C > B
In paid work: n (%) 97 (43) 25 (24) 42 (13) A > B > C
FSS-7 (M ± SD)* 4.7 ± 1.7 3.9 ± 1.6 3.8 ± 1.7 A > B,C
Range 1.0 – 7.0 1.0 – 7.0 1.0 – 7.0
*(Mean ± Standard Deviation).
†Transgender was not included in the analysis of differences between groups with regard to gender.
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found for item #9 (“Fatigue interferes with my work, family,
or social life”) between MS and HIV/AIDS groups (p <
0.01) as well as between stroke and HIV/AIDS groups
(p < 0.05). Our set criterion to support evidence of scale
validity was not met, as multiple items demonstrated sig-
nificant relative DIF when comparing diagnostic groups.
Differences between the generated disease-specific and
disease-generic Rasch person measures of the FSS-7
To compare the generated disease-specific scores from the
three groups with the generated disease-generic scores
(used in the ANOVA comparison), a standardized z-com-
parison was used. None of the 644 person-measures had a
z-value exceeding ±1.96 (z-values ranged from −0.69 to
0.78). These results suggest that the disease-specific item
hierarchies do not heavily influence the individual mea-
sures, as results were comparable to the disease-generic
measure. This was the case even though the three diag-
nostic groups differed with respect to their relative FSS-7
item calibrations.
Discussion
In the present study, fatigue interference, as measured
with the FSS-7, was compared in three chronic illness
samples (MS, stroke, and HIV/AIDS). Overall, the MS
sample demonstrated more fatigue interference than the
stroke and HIV samples. However, four of the seven items
functioned differently for two of the three samples, the-
reby failing to meet the set criterion for stability across
diagnostic groups and raising questions about item validity
across groups. Nonetheless, when disease-specific scores
were compared to the disease-generic scores, person mea-
sures were generally placed in the same position when
considering the level of precision evident in individual
standard errors, thus indicating that individual fatigue
interference in these three chronic illnesses might still be
reliably comparable when using the FSS-7.
The MS group had more fatigue interference than
both the older group of people with stroke and the HIV
group of similar age. These differences may be due to
the fact that almost half of the MS sample was employed
and more were partnered compared to the other two
groups. These findings are also consistent with prior re-
ports of higher prevalence rates of fatigue among people
with MS (55% to 83%) [18-20] than in other groups liv-
ing with chronic illness, including stroke (24% to 77%)
[21,22] and HIV (37% to 65%) [23-25].
With respect to the specific FSS-7 items, people with
HIV/AIDS were less easily fatigued (item #3) than people
with MS or stroke. Given the higher rates of employment
among those with MS and stroke, these groups may be
more likely than people with HIV/AIDS to encounter situ-
ations that demand energy, and thus contribute to fatigue.
In addition, living with a partner, which was more com-
mon among the people with MS or stroke in this study,
has been associated with increased fatigue [2]. Living with
a partner might interfere with adjustments to one’s level of
Table 2 Fatigue severity scale-7: item hierarchy
demonstrated in people with MS
Measure
(SE*) (logit)
Mean (SD†)
(raw score)
Item
Harder items
to agree with
52.57 (.55) 4.37 (2.19) Item 9: Fatigue interferes
with my work, family or
social life
51.85 (.59) 4.43 (2.05) Item 5: Fatigue causes
frequent problems for me
51.08 (.55) 4.60 (2.23) Item 7: Fatigue interferes
with carrying out certain
duties and responsibilities
50.09 (.55) 4.79 (2.22) Item 8: Fatigue is among
my three most disabling
symptoms
49.63 (.55) 4.83 (2.22) Item 6: My fatigue
prevents sustained
physical functioning
47.69 (.62) 4.83 (1.88) Item 3: I am easily fatigued
Easier items to
agree with
47.08 (.59) 5.06 (2.02) Item 4: Fatigue interferes
with my physical
functioning
Items completed by people with MS: all items were completed by n = 224.
*Standard error; †Standard deviation.
Table 3 Fatigue severity scale-7: item hierarchy demonstrated in people with stroke
Measure
(SE*) (logit)
Mean (SD†)
(raw score)
Item
Harder items to agree with 56.32 (.96) 3.23 (1.77) Item 5: Fatigue causes frequent problems for me
54.12 (.95) 3.46 (1.91) Item 9: Fatigue interferes with my work, family or social life
49.54 (.95) 3.93 (2.17) Item 6: My fatigue prevents sustained physical functioning
49.54 (.95) 3.95 (1.95) Item 7: Fatigue interferes with carrying out certain duties and responsibilities
48.18 (.95) 4.10 (2.24) Item 8: Fatigue is among my three most disabling symptoms
46.90 (.96) 4.23 (1.90) Item 3: I am easily fatigued
Easier items to agree with 45.41 (.97) 4.38 (1.67) Item 4: Fatigue interferes with my physical functioning
Items completed by people with stroke: items 3, 4, 5, 7, 8 and 9, n = 104; item 6, n = 103.
*Standard error; †Standard deviation.
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activity in an attempt to manage fatigue and may help
explain the group differences on item #3. In fact, such
contextual issues may potentially be influencing the
hierarchies more than the specific chronic illness.
People with MS were more likely than people with
stroke to agree that fatigue causes frequent problems for
them (item #5). However, differences in the specific pos-
ition of each item may not be as important as overall
hierarchical order, and while item #5 was the hardest
item to agree with for people with stroke and for people
with HIV/AIDS, it was still the second hardest item to
agree with for people with MS. The fact that item #5
was relatively hard for all three diagnostic groups to
agree with may also reflect how people with fatigue learn
to cope, and thereby reduce its impact on their lives.
People who experience low energy often reduce their ac-
tivity according to their perceived capacity for mental
and physical work, and thus their fatigue may not neces-
sarily result in frequent problems [37]. In addition, the
finding that fatigue interference more easily causes prob-
lems for people with MS could reflect ongoing disease
activity or the progression of impairment in people with
MS, which might make it more difficult for them to
compensate for fatigue-related problems.
The samples with MS and HIV/AIDS differed signifi-
cantly regarding the effect of fatigue on sustained phys-
ical functioning (item #6), a difference which might be
explained by the fact that people with MS are more
likely to be bothered by heat sensitivity [3], which is
often regarded as a barrier to being physically active. In
addition, people with HIV/AIDS were more likely than
people with MS or stroke to report that fatigue interferes
with their work, family, or social life (item #9). This
finding may be associated with the experience of stigma,
isolation, and medical disability documented in people
with HIV/AIDS. The extent to which fatigue interfer-
ence adds to the challenges faced by people with HIV/
AIDS needs further research to better understand how it
affects one’s relationships and work life.
The three samples in this study not only differed in
diagnosis, but also differed with respect to nationality,
culture, and language. Thus, the potential influence of
the different social systems in Sweden, Norway, and the
USA on whether and how people perceive fatigue as
Table 4 Fatigue severity scale-7: item hierarchy demonstrated in people with HIV/AIDS
Measure
(SE*) (logit)
Mean (SD†)
(raw score)
Item
Harder items to agree with 52.86 (.50) 3.41 (2.06) Item 5: Fatigue causes frequent problems for me
51.40 (.49) 3.59 (2.01) Item 3: I am easily fatigued
51.10 (.49) 3.65 (1.99) Item 6: My fatigue prevents sustained physical functioning
50.23 (.49) 3.76 (2.13) Item 9: Fatigue interferes with my work, family or social life
49.88 (.49) 3.80 (2.01) Item 7: Fatigue interferes with carrying out certain duties and responsibilities
48.26 (.49) 4.00 (2.24) Item 8: Fatigue is among my three most disabling symptoms
Easier items to agree with 46.27 (.50) 4.28 (2.08) Item 4: Fatigue interferes with my physical functioning
Items completed by people with HIV/AIDS: item 3, n = 313; item 4, n = 312; item 5, n = 315; items 6, 7 and 8, n = 314; item 9, n = 316.
*Standard error; †Standard deviation.
44
46
48
50
52
54
56
58
#3 #4 #5 #6 #7 #8 #9
It
em
 C
al
ib
ra
tio
n 
M
ea
su
re
 (L
og
its
)
Item Number
HIV/AIDS
MS
Stroke
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problematic needs to be considered, particularly since
various social and health care systems place different de-
mands on individuals living with chronic illness. These
additional differences across samples might be consid-
ered a limitation, however, the cultural and language
differences would be expected to increase differences
across diagnostic groups, and yet in our prior psycho-
metric studies of these three groups [15-17], the results
have been quite congruent, providing further evidence
that the FSS-7 is functioning well in different cultural
and diagnostic populations.
The DIF findings pose an interesting interpretative chal-
lenge from a test validity perspective. In general, in order
to conclude that a test is not biased and provide evidence
of cross-diagnostic scale validity, we would expect there to
be no DIF related to diagnosis. Our findings did not sup-
port the validity of FSS-7 from this perspective. However,
the broader issue here relates to whether the findings of
systematic bias are the result of true clinical differences
between the diagnostic groups. The above discussion
about the specific DIF findings suggests that these differ-
ences may have logical and empirical support, and there-
fore not be a major threat to internal scale validity. Still, it
is important to evaluate whether such item calibration dif-
ferences will have an impact when comparing measures
between diagnostic groups. The disease-specific Rasch
person measures of the FSS-7 did not differ from the
disease-generic Rasch person measures, and thus people
are placed in relatively the same place along a continuum
of fatigue interference, irrespective of whether the ge-
nerated Rasch measures are disease-specific or disease-
generic. Based on the findings of this study, we can there-
fore conclude that a generic tool of fatigue may generate
unique diagnostic profiles for different target groups, and
at the same time still generate individual measures of fa-
tigue that are not overly biased by diagnosis.
People with MS, stroke, or HIV/AIDS do experience
fatigue interference differently, as evidenced by the varying
relative item hierarchies and the diagnostic differences in
four of the FSS-7 items. Therefore, comparisons of FSS-7
scores in these populations should be performed with
these issues in mind. The empirical findings from this
study demonstrate that there is a parallel need to also
evaluate DTF when exploring DIF. There is a balancing
act between having sensitive clinical tests that identify
unique clinical profiles for diagnostic groups, and at the
same time allow for valid comparisons of the generated
measures across different samples.
The findings of this study also raise important issues
about the use of generic or specific outcome measures
in health care research. Many concepts used in research
are generic in nature (e.g., quality of life, fatigue, ADL
ability) and not specifically constructed with a particular
diagnosis in mind. By using generic measures and allowing
comparisons between diagnostic groups, we can generate
new knowledge that can be used across diagnoses to
generate a deeper understanding of a target pheno-
menon such as “fatigue”, as well as evaluate potential
therapeutics. However, today the trend is toward using
diagnosis-specific outcome measures for generic pheno-
menon. Although we might assume that this development
allows the test developers to generate more specific items
that may match the unique profile of that specific popula-
tion, there are marked similarities across these diagnosis-
specific measures.
The aim of this study was to evaluate whether the FSS-7
demonstrated similar item hierarchies across people with
MS, stroke, and HIV/AIDS. Given that four items did not
perform in a similar hierarchy for the clinical groups, cau-
tion is warranted when comparing fatigue across diagnos-
tic groups using the FSS-7. However, a replication of this
study using different diagnostic groups is needed to valid-
ate our results on a group level. This could be performed
with larger data sets and/or with item split techniques
[38]. Such studies on item hierarchies in different groups
may also provide a better understanding of diagnostic pro-
files – if and how different groups experience a specific
phenomenon. Such understanding can also be of particu-
lar importance for the evaluation of the effectiveness of
targeted interventions for different diagnostic groups.
Results from the present study are also important to
consider for clinical trials. The effects of a fatigue inter-
vention should not only provide results on sum scores
but should also report changes in the specific item hier-
archies, particularly since an item-specific change might
be the reason an intervention had the reported effect in
a specific diagnostic group or failed to demonstrate the
desired effect. In addition, according to the findings of
this study, both an item reduction and Rasch analysis of
the raw scores of the original FSS would be required to
Table 5 Differential item functioning of fatigue severity
scale-7 by diagnostic groups
Item Differential item functioning
3 MS – HIV/AIDS** Stroke – HIV/AIDS**
4 None
5 MS – Stroke**
6 MS – HIV/AIDS*
7 None
8 None
9 MS – HIV/AIDS** Stroke – HIV/AIDS*
*Indicates significant differences (*p < 0.05; **p < 0.01) using Mantel-Haenszel
statistic for polytomous scales. The statistic indicated significant differential
item function by diagnostic group for items #3 (a relatively more difficult item
for the HIV/AIDS group compared to the MS and stroke groups, #5 (a relatively
easier item for the MS group compared to the stroke group, #6 (a relatively easier
item for the MS group compared to the HIV/AIDS group, and #9 (a relatively
easier item for the HIV/AIDS group compared to the MS or stroke groups). Item
calibrations for items #4, #7, and #8 did not differ by diagnostic group.
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facilitate transfer of such knowledge across diagnostic
groups. Earlier studies showed non-linear relationships
between the item raw sum scores and Rasch-generated
measures of the original FSS, which indicates the risk of
either over- or under-estimating fatigue interference in
people with chronic illness by continuing to use the item
raw sum score of the original FSS [15]. An additional
benefit of using Rasch-generated measures is the provision
of an individual precision estimate (i.e., standard error) for
each client, which minimizes the risk of overestimating
changes or differences on an individual level, as demon-
strated in this study when exploring DTF.
Limitations
In addition to the cultural and language differences men-
tioned above, the main limitation of this study is that the
three diagnostic groups were not matched on any poten-
tially confounding variables which might also explain the
observed group differences. There were limited clinical
and socio-demographic data available for these samples,
and additional detail regarding potentially confounding
variables may have facilitated interpretation of the results,
particularly regarding DIF. One possible strategy could
have been to match the groups regarding age and gender.
However, as these socio-demographic differences probably
reflect true differences between these populations, this
strategy might result in findings that have higher internal
validity, but limited external validity. In addition, possible
variations in depressive symptoms in the different groups
were not taken into account as part of this study. The se-
verity of depressive symptoms can influence how fatigue is
experienced [39] and thus, might have influenced the re-
sults. Another possible confounder which was not taken
into account in the analyses is the fatigue-associated side
effects of various medications. Fatigue is a common side
effect of immunomodulatory medications commonly used
to treat both MS [40] and HIV [41], and future studies
should consider the potential influence of these and other
medications. Although the variation in sample size be-
tween the three groups may have some impact upon their
representativeness and generalizability, a sample size of at
least 100 will generate relatively stable item estimates.
Thus, the variation in sample sizes between the groups is
likely to have minimal impact on the results. Finally, the
current findings can only be generalized to the chronic
illnesses included in this study and warrant exploration in
other populations.
Conclusions
When fatigue interference, as measured with the FSS-7,
was compared across three chronic illnesses (MS, stroke,
and HIV/AIDS), four items functioned differently between
the samples. However, when comparing the disease-specific
scores of the three samples with the disease-generic scores,
person measures were placed in relatively the same man-
ner, thereby suggesting that fatigue interference in these
chronic illnesses might still be reliably compared using
FSS-7 scores. Nonetheless, caution is warranted when
comparing FSS-7 measures across diagnostic groups, and
further studies of the FSS-7 and other symptom measures
are needed.
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